Showing results (581-590 of 13,202) with videos related to
Sort By:
Pageof 1,321
Diabetes Care|November 1, 1992
Fuel and fluid homeostasis during long-term exercise in healthy subjects and type I diabetic patientsV A Koivisto, T Sane, F Fyhrquist, et al.Diabetes Care|November 1, 1992
I'm running on insulin. Summary of the history of the International Diabetic Athletes AssociationU Thurm, P N HarperDiabetes Care|December 25, 2003
Clinical decisions regarding HbA1c results in primary care: a report from CaReNet and HPRNBennett L Parnes, Deborah S Main, L Miriam Dickinson, et al.Diabetes Care|December 25, 2003
Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary reportCarol E Koro, Steven J Bowlin, Nancy Bourgeois, et al.Diabetes Care|December 25, 2003
Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetesJames M Lawrence, Julia Reid, Gordon J Taylor, et al.Diabetes Care|December 25, 2003
Dietary magnesium intake in relation to plasma insulin levels and risk of type 2 diabetes in womenYiqing Song, JoAnn E Manson, Julie E Buring, et al.Diabetes Care|December 25, 2003
Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary careCarel F Schaars, Petra Denig, Willeke N Kasje, et al.Diabetes Care|December 25, 2003
Depressive symptoms and risk of type 2 diabetes in womenCassandra Arroyo, Frank B Hu, Louise M Ryan, et al.Diabetes Care|December 25, 2003
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesMarkolf Hanefeld, Paolo Brunetti, Guntram H Schernthaner, et al.Diabetes Care|December 25, 2003
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsJarl S Torgerson, Jonathan Hauptman, Mark N Boldrin, et al.Pageof 1,321